Upcoming Webinars, FDA Clearances, Preclinical Data Presentations, Completed Acquisitions and Financial Results - Research Report on Teva, Boston Scientific, Alnylam, Wright Medical, and Onconova

NEW YORK, November 25, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Teva Pharmaceutical Industries Limited (NYSE: TEVA), Boston Scientific Corporation (NYSE: BSX), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Wright Medical Group Inc. (NASDAQ: WMGI), and Onconova Therapeutics, Inc. (NASDAQ: ONTX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Teva Pharmaceutical Industries Limited Research Report

On November 19, 2013, Teva Pharmaceutical Industries Limited (Teva) announced that it will unveil new pipeline assets from the NTE program of 2013 at its 2nd Teva R&D In-Focus NTE webinar, to be held on December 4, 2013 at 8:00 a.m. ET. The Company informed that the webinar series will include an in-depth review of certain key projects from the NTE program of 2013 and will outline the global market and unmet needs for each. Dr. Michael Hayden, Teva's President of Global R&D and Chief Scientific Officer, will lead the webinar and will be joined by key leaders from Teva's NTE program. The Full Research Report on Teva Pharmaceutical Industries Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/e3a3_TEVA

--

Boston Scientific Corporation Research Report

On November 19, 2013, Boston Scientific Corp. (Boston Scientific) announced that its Direxion™ Torqueable Microcatheter, a product designed to facilitate selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature, has received U.S. Food and Drug Administration (FDA) clearance and CE Mark approval. "Boston Scientific is committed to supporting interventional radiologists with innovative technologies designed to improve outcomes for patients suffering from challenging conditions such as liver cancer and uterine fibroids," said Jeff Mirviss, President, Peripheral Interventions, Boston Scientific. "The Direxion Torqueable Microcatheter adds a completely new technology to our market-leading peripheral embolization portfolio, and its unique slotted nitinol hypotube technology will provide physicians with unrivaled handling characteristics." The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/5640_BSX

--

Alnylam Pharmaceuticals, Inc. Research Report

On November 17, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it has presented new, pre-clinical data from two RNAi therapeutic programs for cardiovascular disease, including: ALN-PCSsc, for the treatment of hypercholesterolemia; and ALN-ANG, for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia. The data were presented at the American Heart Association (AHA) Scientific Sessions held in Dallas, Texas between November 16, 2013 and November 20, 2013. "Our recent progress with GalNAc-siRNA conjugates enables advancement of subcutaneously administered RNAi therapeutics for the treatment of cardiovascular disease, and our new data presented at the AHA meeting feature our efforts with ALN-PCSsc and ALN-ANG," said Rachel Meyers, Ph.D., Vice President of Research and RNAi Lead Development at Alnylam. "We believe these results support a highly competitive target product profile, and we look forward to advancing ALN-PCSsc toward clinical trials in 2014 with our partner The Medicines Company." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/5b29_ALNY

--

Wright Medical Group Inc. Research Report

On November 15, 2013, Wright Medical Group Inc. (Wright) announced that it has completed the acquisition of Biotech International, a French orthopedic extremities company. According to the Company, the acquisition will further expand Wright's direct sales channel in France and international distribution network, and add Biotech's complementary extremity product portfolio to further accelerate growth opportunities in Wright's global Extremities business. As a result of closing this transaction, the Company now anticipates full-year 2013 net sales to be at the high end of its full-year 2013 net sales range of $237 million to $240 million. The Full Research Report on Wright Medical Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/1782_WMGI

--

Onconova Therapeutics, Inc. Research Report

On November 12, 2013, Onconova Therapeutics Inc. (Onconova) reported its Q3 2013 financial results with total net revenue of $1.1 million compared to $42.8 million in Q3 2012. Research and development expenses came in at $15.3 million, compared to $27.0 million in Q3 2012. The Company reported a net loss of $20.5 million, compared to $1.4 million in Q3 2012. "Onconova made important progress during the third quarter, significantly expanding the clinical development program for our most advanced product candidate, rigosertib, with the initiation of three new clinical trials," commented Ramesh Kumar, Ph.D., President and CEO of Onconova. "We anticipate key upcoming milestones in the development of rigosertib, including the presentation of results from the Phase 2 trial in lower risk myelodysplastic syndromes (MDS); top-line results from the Phase 3 trial in higher risk MDS, and results from an interim analysis of the Phase 3 trial in pancreatic cancer." The Full Research Report on Onconova Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/5181_ONTX

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner